Navigation Links
Micropharma Convenes Expert Roundtable on New Role for Probiotics in Cardiovascular Disease in time for National Cholesterol Education Month
Date:9/5/2012

MONTREAL, Sept. 5, 2012 /PRNewswire/ -- In advance of September's National Cholesterol Education Month, a roundtable of leading global experts in heart health, probiotics and nutrition convened in Chicago to discuss the development of a new scientific review paper looking at a new role for probiotics in cardiovascular disease.

The August 23 roundtable participants included:

  • Richard J. Deckelbaum, MD, CM, FRCPC, Robert R. Williams Professor of Nutrition, Professor of Pediatrics, Professor of Epidemiology, Director, Institute of Human Nutrition, College of Physicians and Surgeons, Columbia University Medical Center, New York
  • Mark L. Dreher, PhD, Nutrition Science Solutions
  • Jacques Genest, MD FRCP(C), Professor, Faculty of Medicine, McGill University; Novartis Chair in Medicine, McGill University; Scientific Director, Center for Innovative Medicine, McGill University Health Center/Royal Victoria Hospital, Montreal
  • Penny M. Kris-Etherton, PhD, RD; Distinguished Professor of Nutrition, Department of Nutritional Sciences, Penn State University, Pennsylvania
  • Mitchell Lawrence Jones, MD, PhD, CSO, Co-Founder, Micropharma, Montreal
  • Volker Mai, PhD, Associate Professor, Department of Epidemiology, College of Public Health and Health Professions and College of Medicine, University of Florida, Florida
  • Christopher John Martoni, PhD, Research Scientist, Micropharma, Montreal
  • Mary Ellen Sanders, PhD, Consultant, Dairy & Food Culture Technologies, Colorado

The roundtable was supported by Micropharma Limited.

Presentation at American Heart Association Scientific Sessions

Dr. Mitchell Jones, Micropharma chief scientific officer and co-founder, will present new clinical results about Cardioviva™ (Lactobacillus reuteri NCIMB 30242) at an oral presentation entitled "Probiotics for Heart Health:  Next Generation of Adjunct Therapies for Lipid Management," at the American Heart Association (AHA) Scientific Sessions on Nov. 5, 2012, in Los Angeles.

The association expects more than 20,000 scientists and healthcare professionals from more than 110 countries to attend the Scientific Sessions. It is the largest gathering devoted to the science of cardiovascular disease and stroke and the care of patients suffering from these diseases.  Results of the research will be available following the presentation.

About Micropharma Limited

Micropharma Limited, headquartered in Montreal, Quebec, is bringing a new approach to the development of over-the-counter healthcare products, medical foods, and biotherapeutics.  Micropharma applies a pathophysiological driven method to developing probiotic and enzyme therapies by focusing first on the health concern and then developing the effective products to support heath in that condition.  For more information, visit http://www.micropharma.net.


'/>"/>
SOURCE Micropharma Limited
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Northwestern University Joins VIVO Network with Elseviers SciVal Experts
2. Inspiration Biopharmaceuticals Expands Industry Expertise with Five New Executive Hires
3. Womens Health Expert GC-Rise Ties up with Georgetown MBA Team to Tap M&A Potential and Growth Strategy
4. UMass Amherst, Harvard experts say better systems needed for medical device cybersecurity
5. Renowned Operations and Supply Chain Expert Dr. David Simchi-Levi Joins OPS Rules
6. Mining cleanup benefits from Texas A&M expertise
7. Maths experts question key ecological theory
8. TAKE Solutions Brings Together Leading Experts and TAKE Customers at “Converge 2012” to Discuss Business
9. Fusion presents low proliferation risk, experts conclude
10. Cancer Immunotherapy Expert Joins Pacific Meso Center Research Team
11. Cepheid Receives FDA Clearance for GeneXpert Infinity-80 System for Initial Use with Xpert Flu Assay
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... -- In today,s pre-market research, Stock-Callers.com takes ... industry: Sangamo Therapeutics Inc. (NASDAQ: SGMO), Eyegate Pharmaceuticals Inc. ... Regulus Therapeutics Inc. (NASDAQ: RGLS ). On ... rating on Pharmaceuticals/Biotechnology to "Overweight" from "Market Weight." Learn more about ... ...
(Date:3/22/2017)... 2017  UBM and the Massachusetts Medical Device ... partnership and the third annual Massachusetts Medtech Week. Massachusetts ... st Annual MassMEDIC Conference held in conjunction ... 2017. MassMEDIC will feature a ... and CEO, Scott Whitaker , at its ...
(Date:3/22/2017)... Florida , March 22, 2017 ... ... various cancer conditions are being pressured as of late due ... for cancer pain management has a dramatic impact on patient,s ... research and development activities for identifying new forms of opioid ...
(Date:3/22/2017)... , ... March 21, 2017 , ... Okyanos Cell Therapy ... as part of their live events series, “Stem Cell Therapy: The Next Phase in ... under the 2013 Stem Cell Research and Therapy Act, Okyanos maintains a ...
Breaking Biology Technology:
(Date:2/14/2017)... N.C. , Feb. 14, 2017  Wake Forest ... M.D., as its new chief executive officer (CEO). Freischlag ... CEO John D. McConnell , M.D., who last ... position at the Medical Center, after leading it since ... the full scope of Wake Forest Baptist,s academic health ...
(Date:2/10/2017)... Feb 10, 2017 Research and ... "Personalized Medicine - Scientific and Commercial Aspects" to ... ... Diagnosis is integrated with therapy for selection of treatment as ... detection and prevention of disease in modern medicine. Biochip/microarray technologies ...
(Date:2/8/2017)... BEDFORD, Mass., Feb. 7, 2017  Aware, Inc. (NASDAQ: ... services, today reported financial results for its quarter and year ... fourth quarter of 2016 was $3.9 million compared to $6.9 ... the fourth quarter of 2016 was $0.6 million compared to ... in the fourth quarter of 2016 was $0.5 million, or ...
Breaking Biology News(10 mins):